Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Abstract The International Prognostic Scoring Sytem (IPSS) is an important standard for
ssessing prognosis of primary untreated adult patients with myelodysplastic syndromes …

This review gives an account of the clinical and hematologic features of the myelodysplastic
syndromes. It supplies the latest classification of these disorders, discusses the cytogenetic …

Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …

We have generated a large, unique database that includes morphologic, clinical,
cytogenetic, and follow-up data from 2124 patients with myelodysplastic syndromes (MDSs) …

The classification, scoring systems, and response criteria for myelodysplastic syndromes
(MDS) have recently been updated and have become widely accepted. In addition, several …

The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but
have otherwise very heterogeneous biological and genetic characteristics. Clinical features …

Oncogenic pathways underlying in the development of myelodysplastic syndromes (MDS)
remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are …

Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases
characterized by profound heterogeneity in morphologic presentation, clinical course, and …